Epidemiology of antiretroviral multiclass resistance

American Journal of Epidemiology

Volumn 172, Issue 4, 2010, Pages 460-468

  Lima, Viviane D ^a,b   Harrigan, P Richard ^a,b   Sénécal, Martin ^c   Yip, Benita ^a   Druyts, Eric ^d   Hogg, Robert S ^a,e   Montaner, Julio S G ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^d Independent Consultant   (Canada)

^e SIMON FRASER UNIVERSITY   (Canada)

Author keywords

antiretroviral therapy; drug resistance; highly active; HIV; medication adherence; patient compliance; viral load

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

DRUG RESISTANCE; EPIDEMIOLOGY; FREQUENCY ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS; INHIBITOR; LOGISTICS; NUMERICAL MODEL; SURVIVAL;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; SURVIVAL; VIRUS LOAD; CANADA; DRUG EFFECTS; HIV INFECTIONS; MIDDLE AGED; PROSPECTIVE STUDY; REGRESSION ANALYSIS;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; VIRAL LOAD;

BRITISH COLUMBIA; CANADA;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77955873085     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq101     Document Type: Article

References (26)

1. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. International AIDS Society-USA. JAMA. 2008;300(5):555-570.
2. Lima VD, Gill VS, Yip B, et al. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis. 2008;198(1):51-58.
3. Tan R, Westfall AO, Willig JH, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immu-nologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(5):553-558.
4. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50(5):529-536.
5. Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr. 2008;49(3):266-271.
6. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among nä?ve HIV-infected individuals. AIDS. 2008;22(17):2371-2380.
7. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344(7):472-480.
8. Siliciano RF. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Top HIV Med. 2005;13(3):96-100.
9. Sax PE. Therapeutic options for treatment experienced patients: a focus on resistance testing and optimizing background therapy. AIDS Read. 2006;16(5):265-275, 277-278.
10. Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr. 2006;41(3):323-331.
11. Erratum in: J Acquir Immune Defic Syndr. 2006;43(3):381.
12. Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. AIDS. 2005;19(5):487-494.
13. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724. (doi: 10.1371/journal. pone.0004724).
14. Plank RM, Kuritzkes DR. An update on HIV-1 antiretroviral resistance. Curr Opin HIV AIDS. 2006;1(5):417-423.
15. Pillay D, Green H, Matthias R, et al. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. UK Collaborative Group on HIV Drug Resistance. J Infect Dis. 2005;192(6):967-973.
16. Lima V, Hudson E, Wynhoven B, et al. Drastically declining incidence of HIV drug resistance: the end of the beginning? [abstract 895]. Presented at the 15th Conference on Retrovi-ruses and Opportunistic Infections, Boston, Massachusetts, February 3-6, 2008.
17. Bracciale L, Di Giambenedetto S, Colafigli M, et al. Viro-logical suppression reduces clinical progression in patients with multiclass-resistant HIV type 1. AIDS Res Hum Retrovi-ruses. 2009;25(3):261-267.
18. Zöllner B, Feucht HH, Weitner L, et al. Application of HIV-1 genotypic-resistance testing prevents the evolution of further resistance mutations in heavily pretreated patients. J Clin Viro L. 2001;21(1):37-45.
19. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15(4):119-125.
20. Hosmer D Jr, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons; 2000.
21. 3 in Mexico [abstract TUAB0104]. Presented at the 17th International AIDS Conference: Mexico City Mexico, August 3-8 2008
22. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. DUET-1 Study Group. Lancet. 2007;370(9581):29-38.
23. Owen A, Khoo SH. Pharmacogenetics of antiretroviral agents. Curr Opin HIV AIDS. 2008;3(3):288-295.
24. van Roey J, von Schoen-Angerer T, Ford N, et al. How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. Drug Discov Today. 2008;13(13-14):601-605.
25. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. BHIVATreatment Guidelines Writing Group. HIV Med. 2008;9(8):563-608.
26. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191(3): 339-347.